DiaMedica Therapeutics Inc  

(Public, CVE:DMA)   Watch this stock  
Find more results for DMA
+0.045 (25.71%)
Feb 23 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.18 - 0.22
52 week 0.14 - 0.22
Open 0.18
Vol / Avg. 440,925.00/147,994.00
Mkt cap 22.39M
P/E     -
Div/yield     -
EPS -0.03
Shares 110.51M
Beta -0.19
Inst. own     -

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -213.55% -629.99%
Return on average equity -1269.96% -
CDP Score - -


2 Carlson Pkwy N # N165
MINNEAPOLIS, MN 55447-4466
United States - Map
+1-763-2700603 (Phone)
+1-763-7104456 (Fax)

Website links


DiaMedica Therapeutics Inc is a Canada-based clinical-stage biopharmaceutical company, which focuses on recombinant proteins and monoclonal antibodies. The Company focuses on the discovery and development of treatments for stroke and other vascular diseases. It operates through segment, which is discovery and development of recombinant proteins and monoclonal antibody technology applications to treat large unmet diseases, including acute vascular disease of the brain, kidneys and heart. Its product, DM199, is a recombinant human tissue kallikrein-1 protein engineered to duplicate the actions of the naturally occurring human kallikrein-1 protein produced in the pancreas, kidneys and salivary glands of humans as a response to oxidative stress challenges. Its drug, Recombinant tissue plasminogen activator, is intended for the treatment of acute ischemic stroke (AIS). DM199 has also completed a Phase I/II clinical trials in Type 2 diabetic patients.

Officers and directors

Richard D. Pilnik Independent Chairman of the Board
Age: 57
Rick Pauls President, Chief Executive Officer, Director
John Savage CPA Chief Financial Officer
Todd A. Verdoorn Ph.D. Chief Scientific Officer
David Aaron Gurvey Vice President - Finance
Paul Papi Vice President - Business Development
Dennis D. Kim M.D. Consulting Chief Medical Officer
Age: 46
James T. Parsons CPA Corporate Secretary, Director
Jerry Xiao Director
Michael Giuffre M.D. Independent Director